NPORT-EX 2 NPORT_9ETD_28568980_1021.htm BlackRock Future Health ETF

Schedule of Investments  (unaudited)

October 31, 2021

   

BlackRock Future Health ETF

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Common Stocks

    
Biotechnology — 33.3%            

Acceleron Pharma Inc.(a)

    946     $ 164,774  

Acumen Pharmaceuticals Inc.(a)

    502       7,053  

Agios Pharmaceuticals Inc.(a)

    1,192       56,024  

Allakos Inc.(a)(b)

    563       56,627  

Alnylam Pharmaceuticals Inc.(a)

    695       110,894  

ALX Oncology Holdings Inc.(a)

    175       9,807  

Ambrx Biopharma Inc., ADR(a)

    322       4,057  

Annexon Inc.(a)

    460       7,503  

Apellis Pharmaceuticals Inc.(a)

    461       14,171  

Applied Molecular Transport Inc.(a)

    416       9,368  

Arcus Biosciences Inc.(a)

    389       13,008  

Arcutis Biotherapeutics Inc.(a)

    1,267       26,835  

Arena Pharmaceuticals Inc.(a)

    546       31,335  

Argenx SE, ADR(a)(b)

    325       98,137  

Arrowhead Pharmaceuticals Inc.(a)

    230       14,679  

Beam Therapeutics Inc.(a)

    87       7,723  

BioAtla Inc.(a)

    350       10,231  

Biohaven Pharmaceutical Holding Co. Ltd.(a)

    278       39,565  

BioMarin Pharmaceutical Inc.(a)

    743       58,868  

Blueprint Medicines Corp.(a)

    482       54,220  

Bridgebio Pharma Inc.(a)

    561       27,702  

C4 Therapeutics Inc.(a)

    854       37,935  

Connect Biopharma Holdings Ltd.(a)

    159       2,519  

Cytokinetics Inc.(a)(b)

    698       24,367  

Decibel Therapeutics Inc.(a)

    353       2,863  

Deciphera Pharmaceuticals Inc.(a)

    407       13,590  

Design Therapeutics Inc.(a)

    183       2,869  

Dicerna Pharmaceuticals Inc.(a)

    1,086       22,600  

Enanta Pharmaceuticals Inc.(a)

    363       31,164  

Fate Therapeutics Inc.(a)

    123       6,617  

Genmab A/S(a)

    387          173,860  

Genmab A/S, ADR(a)(b)

    1,730       77,227  

Gritstone bio Inc.(a)

    715       7,858  

Horizon Therapeutics PLC(a)

    567       67,989  

Icosavax Inc.(a)

    1,548       40,496  

Ideaya Biosciences Inc.(a)

    804       17,238  

Imago Biosciences Inc.(a)

    310       8,252  

Immuneering Corp., Class A(a)

    168       4,553  

Immunocore Holdings PLC(a)

    150       5,778  

Iovance Biotherapeutics Inc.(a)

    526       12,787  

Kadmon Holdings Inc.(a)

    5,670       53,581  

Karuna Therapeutics Inc.(a)

    201       28,216  

Keros Therapeutics Inc.(a)

    573       23,906  

Kinnate Biopharma Inc.(a)(b)

    633       15,046  

Kodiak Sciences Inc.(a)

    207       24,238  

Krystal Biotech Inc.(a)

    67       3,356  

Kymera Therapeutics Inc.(a)

    681       40,097  

Mirati Therapeutics Inc.(a)

    227       42,908  

Monte Rosa Therapeutics Inc.(a)(b)

    344       8,067  

Morphic Holding Inc.(a)

    239       13,743  

Natera Inc.(a)

    1,196       137,026  

Neurocrine Biosciences Inc.(a)

    210       22,136  

Olema Pharmaceuticals Inc.(a)

    573       15,471  

Omega Therapeutics Inc.(a)(b)

    276       8,109  

Prometheus Biosciences Inc.(a)

    710       22,621  

Prothena Corp. PLC(a)

    910       50,368  

RAPT Therapeutics Inc.(a)

    473       14,937  

REVOLUTION Medicines Inc.(a)

    609       17,923  
Security   Shares     Value  
Biotechnology (continued)            

Sarepta Therapeutics Inc.(a)

    489     $ 38,695  

Seagen Inc.(a)

    1,252       220,765  

Sigilon Therapeutics Inc.(a)

    722       3,892  

Talaris Therapeutics Inc.(a)

    287       4,847  

Taysha Gene Therapies Inc.(a)

    449       7,022  

Tenaya Therapeutics Inc.(a)

    354       9,101  

TScan Therapeutics Inc., NVS(a)

    1,378       12,071  

Twist Bioscience Corp.(a)

    54       6,415  

United Therapeutics Corp.(a)

    161       30,712  

Vertex Pharmaceuticals Inc.(a)

    192       35,507  

Zai Lab Ltd., ADR(a)

    256       26,726  

Zentalis Pharmaceuticals Inc.(a)

    616       49,551  
   

 

 

  
      2,370,196  
Diversified Financial Services — 1.4%            

DA32 Life Science Tech Acquisition Corp., Class A, NVS(a)

    3,181       31,174  

Eucrates Biomedical Acquisition Corp.(a)

    1,857       18,161  

Health Assurance Acquisition Corp., Class A(a)

    2,816       27,681  

Helix Acquisition Corp., Class A(a)(b)

    445       4,450  

MedTech Acquisition Corp./NY, Class A(a)

    1,908       18,985  
   

 

 

  
      100,451  
Electronic Equipment, Instruments & Components — 0.3%  

908 Devices Inc.(a)(b)

    648       21,319  
   

 

 

  
Health Care Equipment & Supplies — 29.2%  

ABIOMED Inc.(a)

    424       140,785  

Alcon Inc.(b)

    2,110       175,889  

ConvaTec Group PLC(c)

    11,764       34,421  

Cooper Companies Inc. (The)

     285       118,822  

Demant A/S(a)

    1,120       54,295  

DENTSPLY SIRONA Inc.

     1,627       93,081  

Dexcom Inc.(a)

    139       86,626  

Edwards Lifesciences Corp.(a)

    759       90,943  

Globus Medical Inc., Class A(a)

    230       17,749  

Hill-Rom Holdings Inc.

     393       60,876  

Insulet Corp.(a)

    385       119,358  

Intuitive Surgical Inc.(a)

    602       217,400  

Masimo Corp.(a)

    505       143,188  

Novocure Ltd.(a)

    55       5,641  

Nyxoah SA, NVS(a)

    1,368       34,268  

Penumbra Inc.(a)

    147       40,653  

Pulmonx Corp.(a)

    245       9,538  

ResMed Inc.

     456       119,887  

SI-BONE Inc.(a)

    368       8,298  

Sonova Holding AG, Registered

     194       80,388  

STERIS PLC

     374       87,419  

Straumann Holding AG, Registered

     20       41,634  

Tandem Diabetes Care Inc.(a)

    372       50,715  

Teleflex Inc.

     389       138,850  

Zimmer Biomet Holdings Inc.

     789       112,922  
   

 

 

  
      2,083,646  
Health Care Providers & Services — 5.7%            

Addus HomeCare Corp.(a)

    111       10,378  

Agilon Health Inc.(a)(b)

    634       15,533  

Alignment Healthcare Inc.(a)

    780       15,491  

Amplifon SpA

     1,748       88,953  

Centene Corp.(a)

    963       68,604  

Encompass Health Corp.

     1,040       66,102  

Guardant Health Inc.(a)

    329       38,424  

Innovage Holding Corp.(a)

    182       1,205  
 

 

 

1

     

Schedule of Investments  (unaudited) (continued)

October 31, 2021

   

BlackRock Future Health ETF

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Health Care Providers & Services (continued)            

Privia Health Group Inc.(a)

    297     $ 7,633  

Quest Diagnostics Inc.

     477       70,014  

Rede D’Or Sao Luiz SA(c)

    2,099       21,943  
   

 

 

  
      404,280  
Health Care Technology — 0.3%            

Definitive Healthcare Corp.(a)(b)

    322       12,925  

Sophia Genetics SA, NVS(a)

    619       8,784  
   

 

 

  
      21,709  
Life Sciences Tools & Services — 18.0%            

Avantor Inc.(a)

    4,583       185,061  

Bruker Corp.

     921       73,956  

Charles River Laboratories International Inc.(a)

    245       109,927  

Cytek Biosciences Inc.(a)

    1,786       40,739  

ICON PLC(a)(b)

    800       229,416  

Illumina Inc.(a)

    163       67,655  

IQVIA Holdings Inc.(a)

    391       102,215  

IsoPlexis Corp, NVS(a)

    360       4,590  

Lonza Group AG, Registered

     96       78,893  

Olink Holding AB, ADR(a)(b)

    63       2,026  

QIAGEN NV(a)

    2,354       131,259  

Rapid Micro Biosystems Inc., Cass A(a)

    241       4,914  

Sotera Health Co.(a)

    2,797       69,086  

Thermo Fisher Scientific Inc.

     210       132,945  

Wuxi Biologics Cayman Inc., New(a)(c)

    3,500       53,014  
   

 

 

  
      1,285,696  
Pharmaceuticals — 4.9%            

Astellas Pharma Inc.

     4,700       79,236  

Daiichi Sankyo Co. Ltd.

     4,700       118,592  

Merck KGaA

     214       50,574  

Nektar Therapeutics(a)

    890       13,492  

UCB SA

     749       89,525  
   

 

 

  
      351,419  
   

 

 

  

Total Common Stocks — 93.1%
(Cost: $5,466,805)

       6,638,716  
   

 

 

  
Security   Shares     Value  

Warrants

    
Diversified Financial Services — 0.0%            

Eucrates Biomedical Acquisition Corp., (Expires 12/14/25)(a)

    619     $ 526  

Health Assurance Acquisition Corp., (Expires 11/12/25)(a)

    704       676  

MedTech Acquisition Corp./NY, (Expires 12/18/25)(a)

    636       617  
   

 

 

  
      1,819  
   

 

 

  

Total Warrants — 0.0%
(Cost: $4,671)

       1,819  
   

 

 

  

Short-Term Investments

    
Money Market Funds — 16.1%            

BlackRock Cash Funds: Institutional, SL Agency Shares, 0.05%(d)(e)(f)

    606,058       606,361  

BlackRock Cash Funds: Treasury, SL Agency Shares, 0.00%(d)(e)

    540,000       540,000  
   

 

 

  
      1,146,361  
   

 

 

  

Total Short-Term Investments — 16.1%
(Cost: $1,146,361)

       1,146,361  
   

 

 

  

Total Investments in Securities — 109.2%
(Cost: $6,617,837)

       7,786,896  

Other Assets, Less Liabilities — (9.2)%

       (655,726 ) 
   

 

 

  

Net Assets — 100.0%

     $ 7,131,170  
   

 

 

  

 

(a) 

Non-income producing security.

(b) 

All or a portion of this security is on loan.

(c) 

Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

(d) 

Affiliate of the Fund.

(e) 

Annualized 7-day yield as of period end.

(f) 

All or a portion of this security was purchased with the cash collateral from loaned securities.

 

 

Affiliates

Investments in issuers considered to be affiliate(s) of the Fund during the period ended October 31, 2021 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated Issuer   Value at
07/31/21		     

Purchases

at Cost

     Proceeds
from Sales		      Net Realized
Gain (Loss)		      Change in
Unrealized
Appreciation
(Depreciation)		      Value at
10/31/21		      Shares
Held at
10/31/21		      Income    

Capital

Gain

Distributions

from

Underlying

Funds

  

BlackRock Cash Funds: Institutional, SL Agency Shares

   $ 185,281      $ 421,080 (a)    $ —      $ —      $ —      $ 606,361        606,058      $ 316 (b)    $ —  

BlackRock Cash Funds: Treasury, SL Agency Shares

     430,000        110,000 (a)      —        —        —        540,000        540,000        4       —  
         

 

 

     

 

 

     

 

 

        

 

 

    

 

 

  
          $ —      $ —      $ 1,146,361         $ 320     $ —  
         

 

 

     

 

 

     

 

 

        

 

 

    

 

 

  

 

  (a) 

Represents net amount purchased (sold).

 
  (b) 

All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

 

 

 

    

2

Schedule of Investments  (unaudited) (continued)

October 31, 2021

   

BlackRock Future Health ETF

 

Fair Value Measurements

Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:

  •  

Level 1 – Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that each Fund has the ability to access;

  •  

Level 2 – Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs); and

  •  

Level 3 – Unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the BlackRock Global Valuation Methodologies Committee’s (the “Global Valuation Committee’s”) assumptions used in determining the fair value of financial instruments).

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Global Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds. There may not be a secondary market, and/or there are a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Fund’s policy regarding valuation of financial instruments, refer to its most recent financial statements.

The following table summarizes the Fund’s financial instruments categorized in the fair value hierarchy. The breakdown of the Fund’s financial instruments into major categories is disclosed in the Schedule of Investments above.

 

         
     Level 1      Level 2      Level 3      Total  

Investments

           

Assets

           

Common Stocks

   $ 5,729,752      $ 908,964      $         —      $ 6,638,716  

Warrants

     1,819        —        —        1,819  

Money Market Funds

     1,146,361        —        —        1,146,361  
 

 

 

     

 

 

     

 

 

     

 

 

  
  $ 6,877,932      $ 908,964      $ —      $ 7,786,896  
 

 

 

     

 

 

     

 

 

     

 

 

  

 

Portfolio Abbreviations - Equity

ADR

   

American Depositary Receipt

NVS

   

Non-Voting Shares

 

 

 

3